Please use this identifier to cite or link to this item:
|Title:||CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects|
|Citation:||Chan, M.Y., Tan, K., Tan, H.-C., Huan, P.-T., Li, B., Phua, Q.-H., Lee, H.-K., Lee, C.-H., Low, A., Becker, R.C., Ong, W.-C., Richards, M.A., Salim, A., Tai, E.-S., Koay, E. (2012-04). CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects. Pharmacogenomics 13 (5) : 533-542. ScholarBank@NUS Repository. https://doi.org/10.2217/pgs.12.24|
|Abstract:||Aim, materials & methods: We investigated the functional significance of CYP2C19*2, *3, *17 and PON1 Q192R SNPs in 89 consecutive Asian patients on clopidogrel treatment and the prevalence of functionally significant polymorphisms among 300 Chinese, Malays and Asian Indians. Results: Both CYP2C19 loss-of-function alleles (*2 or *3) were associated with higher platelet reactivity while the CYP2C19 gain-of-function allele (*17) had lower platelet reactivity. For PON1, the median PRI was not significantly different between the QQ, QR and RR groups. The allele frequencies of CYP2C19*2, CYP2C19*3 and CYP2C19*17 were 0.280, 0.065 and 0.010 (rare) for Chinese, 0.310, 0.050 and 0.025 for Malays, and 0.375, 0.010 (rare) and 0.165 for Indians, respectively. Conclusion: Our data suggest that genotyping studies to investigate clopidogrel response should include CYP2C19*2 and *3 but not *17 polymorphisms in Chinese, and CYP2C19*2 and *17 polymorphisms but not *3 in Indians. All three polymorphisms should preferably be genotyped in Malays. Original submitted 16 December 2011; Revision submitted 16 February 201. © 2012 Future Medicine Ltd.|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jun 13, 2018
WEB OF SCIENCETM
checked on Apr 24, 2018
checked on May 18, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.